DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a reduction in the ...
Please provide your email address to receive an email when new articles are posted on . Phase 3 clinical trial included 134 adults with full neuroaxis MRI and no new NMOSD symptoms. At 28 weeks, 15% ...
There are predominantly 2 patterns of NMOSD: monophasic and relapsing. Monophasic NMOSD is diagnosed in approximately 10% of patients and occurs when 1 or both optic nerves and spinal cord are ...
"[There is] an opportunity within the healthcare space to create tools within the electronic medical record system that more effectively link symptoms and their duration, diagnostic study results, and ...
BARCELONA, Spain — For the first time in a decade, diagnostic criteria for neuromyelitis optica spectrum disorder (NMOSD) are being overhauled, with changes that redefine the condition and its ...
"The key learning from this work is that timely treatment transitions may hold equatable benefit to the prescribed treatments themselves… the time between moving from one treatment to another was ...
Dublin, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The "Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report provides an ...
Clinical Presentation Common symptoms of NMOSD result from damage to the optic nerve, spinal cord, and brainstem. These include optic neuritis with symptoms of loss or blurred vision in 1 or both eyes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback